Episode 21 - Expectations for Newly Developing Agents

During this segment, the panelists explore newer therapeutic agents that are now receiving a lot of attention in the healthcare market for the management of cardiovascular health, and discuss which products have the greatest potential when treating cardiometabolic events.

David Calabrese, RPh, MHP, discusses the large number of late-phase agents that are available to treat diabetes and believes that product variety allows clinicians to tailor treatment specifically to the patient.

Additionally, Kenneth L. Schaecher, MD, FACP, CPC, discusses the potential of vaccine therapy and gene therapy, which are currently being studied for the treatment of type 1 diabetes.

Yehuda Handelsman, MD, FACP, FACE, FNLA, concludes the discussion by summarizing the most promising products available to treat other cardiometabolic events such as lipid disorders and obesity.